Yumeng Zhang

Yumeng Zhang practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Yumeng Zhang's NPI, 1649701137, was assigned on March 25, 2017. Yumeng Zhang graduated from USF Health Morsani College of Medicine in 2017. Yumeng Zhang holds Florida license ME138364.

Yumeng Zhang's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612. Yumeng Zhang also practices at H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., 10920 McKinley Dr, Tampa, FL 33612.

Yumeng Zhang's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. Yumeng Zhang is also affiliated with Sarasota Memorial Hospital - Sarasota Campus. The medical group on file is Moffitt Cancer Center. Dmand AI also links Yumeng Zhang to 1 more breast imaging center, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Yumeng Zhang practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Yumeng Zhang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Yumeng Zhang is board certified in hematology by the American Board of Internal Medicine. Yumeng Zhang is licensed in Florida.

Dmand AI lists lymphoma among the conditions Yumeng Zhang treats.

CMS data shows 161 Medicare services from Yumeng Zhang across 4 procedure codes in 2024, for 68 Medicare patients. Medicare paid $13,624 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 68 Medicare patients who saw Yumeng Zhang in 2024. The largest group is 65 to 74, with 33 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Yumeng Zhang's median patient age at 68, with 48% women.

In 2024, Yumeng Zhang wrote 118 Medicare Part D claims for 35 patients. 80% of them were for generic drugs. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $250 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Yumeng Zhang for performance year 2024, reported as part of a group. Yumeng Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Yumeng Zhang as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 39 papers to Yumeng Zhang, published from 2015 to 2025. 2022 was the busiest year, with 9. The most frequent topics are Antineoplastic Agents, Actin Cytoskeleton and Angiomotins. Yumeng Zhang has published most often in Am J Hematol. Yumeng Zhang's most frequent co-authors are Lubomir Sokol, MD, David Matthew Rutenberg, DO and Ankita Tandon, DO.

CMS Open Payments shows 85 general payments to Yumeng Zhang from 23 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 61% of the total. Acrotech Biopharma LLC paid the most, $25,974.

Yumeng Zhang graduated from USF Health Morsani College of Medicine in 2017.

Yumeng Zhang is in network with 6 carriers, including United Healthcare, Blue Cross Blue Shield of Michigan and Alliant Health Plans. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.